Join the members of the Ethics Special Interest Group for a lively discussion on the applicability of ethical considerations in the business setting. You’ll examine case scenarios in health care, focusing on genetics and appropriate disclosures, as well as the compelling case of Enron.

**Content Area:** Clinical Practice

**Content Level:** Intermediate

**Coordinator/Speaker:**
Laura Beamer, DNP, NP, AOCNS®, AOCNP®
Assistant Professor
Northern Illinois University
DeKalb, IL
labeamer@gmail.com

**Full Disclosure:**
Nothing to Disclose

**Speaker:**
Gabriela Kaplan, RN, MSN, AOCN®
Clinical Nurse Specialist, Oncology Care Alternatives Hospice
Cranford, NJ
gabiaocn@gmail.com

**Full Disclosure:**
Nothing to Disclose

**Speaker:**
G. Jean Logan, DRNP(C),MSN, RN
Doctoral Candidate
Drexel University
jeanloganrn@gmail.com

**Full Disclosure:**
Nothing to Disclose

**Content Outline:**
Business meeting (30 minutes)
I. Approve 2014 meeting agenda.
II. Approve minutes from the 2013 meeting.
III. Introduction of the Ethics SIG leaders
IV. Open positions
V. Recognition award
VI. Raffle
VII. 25th anniversary celebration

**Educational session (60 minutes)**
I. Enron
   A. What exactly happened?
   B. Brief overview of opaque business practices
      1. The bottom line
      2. The end result
   II. Case example of an issue related to a nursing conference
      A. Overview of the “missed disclosure”
      B. Ramifications of an “unqualified speaker”
         1. Disclosure post conference?
         2. Responsibility of the person who discovers
            a. Is it a moral/ethical imperative?
            b. To whom should the report be made?
            c. How far “up the line” should one report?
      C. Discussion
   III. The case of the self-serving urologists
      A. Contextual features of the case
      B. Concerns of the American Society for Radiation Oncology (ASTRO)
      C. Ethics in Patient Referrals Act of 1989 (Stark Law)
         1. Inclusions and exceptions
         3. Whistleblower Ombudsman
      E. Promoting Integrity in Medicare Act (PIMA) of 2013
      F. Discussion
   IV. Who owns your DNA?
      A. Plaintiffs: Myriad Genetics, the USPTO, the University of Utah Research Foundation
      B. Complainants: Association of Molecular Pathologists, the American Civil Liberties Union, and a coalition of other groups
      C. Concern: Constitutionality of BRCA1/2 patents
      D. United States District Court for the Southern District of New York (March 2010)
      E. Court of Appeals for the Federal Circuit (2010, 2011)
      F. U.S. Supreme Court returns the case to the Federal Court (2012)
      G. U.S. Supreme Court (2013) final ruling
      H. Discussion